— Know what they know.
Not Investment Advice

XLO NASDAQ

Xilio Therapeutics, Inc.
1W: -0.3% 1M: +1.9% 3M: -4.6% YTD: +1241.4% 1Y: +982.1% 3Y: +327.0%
$9.01
+0.10 (+1.12%)
 
Weekly Expected Move ±2.0%
$9 $9 $9 $9 $9
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 51 · $59.2M mcap · 2M float · 1.12% daily turnover · Short 40% of daily vol

Balance Sheet Trends

Total Assets
$155M +117.6% ▲
5Y CAGR: +33.6%
Total Liabilities
$119M +123.3% ▲
5Y CAGR: +23.5%
Shareholders Equity
$35M +100.4% ▲
Cash & Investments
$138M +148.7% ▲
5Y CAGR: +48.2%
Total Debt
$7M -14.6% ▼
5Y CAGR: -20.5%
Net Debt
-$131M -176.9% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$198M$120M$45M$55M$138M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$198M$120M$45M$55M$138M
Net Receivables$0$0$0$0$5M
Inventory$0$0$0$0$0
Other Current Assets$4M$4M$3M$5M$2M
Total Current Assets$203M$124M$48M$60M$145M
Property, Plant & Equip.$14M$13M$11M$9M$8M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$2M$2M$0$2M$2M
Other Non-Current Assets$90K$267K$2M$0$0
Total Non-Current Assets$19M$15M$13M$11M$10M
Total Assets$222M$139M$61M$71M$155M
— Liabilities —
Accounts Payable$3M$3M$1M$3M$3M
Short-Term Debt$883K$7M$3M$0$1M
Deferred Revenue$0$0$0$14M$40M
Other Current Liabilities$4M$82K$7M$4M$12M
Total Current Liabilities$13M$21M$16M$27M$56M
Long-Term Debt$10M$3M$0$0$0
Other Non-Current Liab.$0$45K$0$0$58M
Total Non-Current Liabilities$23M$12M$8M$26M$63M
Total Liabilities$36M$34M$24M$53M$119M
— Equity —
Common Stock$3K$3K$3K$5K$37M
Retained Earnings-$161M-$249M-$326M-$384M-$419M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity$185M$106M$37M$18M$35M
Total Liabilities & Equity$222M$139M$61M$71M$155M
— Key Metrics —
Total Debt$21M$20M$11M$8M$7M
Net Debt-$177M-$100M-$33M-$47M-$131M
Total Investments$2M$2M$0$2M$2M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms